Efficacy of pentoxifylline treatment for neonatal sepsis: a meta-analysis of randomized controlled studies

摘要

Pentoxifylline may be an important approach to treat neonatal sepsis. However, its use has not been well established. We conduct a systematic review and meta-analysis to evaluate the efficacy of pentoxifylline treatment for neonatal sepsis. PubMed, Embase, and the Cochrane Central Register of Controlled Trials are searched. Randomized controlled trials (RCTs) assessing the influence of pentoxifylline treatment on neonatal sepsis are included. Two investigators independently have searched articles, extracted data, and assessed the quality of included studies. This meta-analysis is performed using the random-effect model. Seven RCTs involving 439 patients are included in the meta-analysis. Compared with control intervention for neonatal sepsis, pentoxifylline treatment is associated with reduced hospital stay (Std. MD?=?-0.61; 95% CI?=?-0.93 to ??0.29; P?=?0.0002) and metabolic acidosis (RR?=?0.38; 95% CI?=?0.22 to 0.66; P?=?0.0006), but has no remarkable impact on mortality (RR?=?0.59; 95% CI?=?0.30 to 1.16; P?=?0.13), serum TNF-α (Std. MD?=?-0.38; 95% CI?=?-1.29 to 0.52; P?=?0.41), serum CRP (Std. MD?=?-0.25; 95% CI?=?-0.92 to 0.42; P?=?0.47), plasma IL-6 (Std. MD?=?-0.13; 95% CI?=?-0.41 to 0.15; P?=?0.37), disseminated intravascular coagulopathy (RR?=?0.55; 95% CI?=?0.25 to 1.21; P?=?0.14), and oliguria/anuria (RR?=?0.77; 95% CI?=?0.28 to 2.16; P?=?0.62). In addition, pentoxifylline treatment can significantly reduce mortality (RR?=?0.50; 95% CI?=?0.29 to 0.88; P?=?0.02) after excluding the study conducted by Akdag during the sensivity analysis. Pentoxifylline treatment may be associated with reduced mortality and hospital stay in neonatal sepsis.